Singular Genomics Systems, Inc.

NasdaqGS:OMIC Stock Report

Mkt Cap: US$177.1m

We’ve recently updated our valuation analysis.

Singular Genomics Systems Valuation

Is OMIC undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for OMIC?

Other financial metrics that can be useful for relative valuation.

OMIC key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenuen/a
Enterprise Value/EBITDAn/a
PEG Ration/a

Price to Book Ratio vs Peers

How does OMIC's PB Ratio compare to its peers?

The above table shows the PB ratio for OMIC vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPBEstimated GrowthMarket Cap
Peer Average2.4x
NOTV Inotiv
0.5x125.2%US$182.7m
TKNO Alpha Teknova
1.5x18.9%US$164.3m
NAUT Nautilus Biotechnology
0.7x-20.2%US$240.7m
CDXC ChromaDex
7x67.5%US$147.1m
OMIC Singular Genomics Systems
0.6x-1.3%US$177.1m

Price-To-Book vs Peers: OMIC is good value based on its Price-To-Book Ratio (0.6x) compared to the peer average (2.4x).


Price to Earnings Ratio vs Industry

How does OMIC's PE Ratio compare vs other companies in the US Life Sciences Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a14.2%
n/an/an/a

Price-To-Book vs Industry: OMIC is good value based on its Price-To-Book Ratio (0.6x) compared to the US Life Sciences industry average (2.3x)


Price to Book Ratio vs Fair Ratio

What is OMIC's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

OMIC PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio0.6x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate OMIC's Price-To-Book Fair Ratio for valuation analysis.


Share Price vs Fair Value

What is the Fair Price of OMIC when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate OMIC's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate OMIC's fair value for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst OMIC forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$2.48
US$2.63
+6.2%
10.0%US$3.00US$2.40n/a3
Jan ’24US$2.01
US$2.83
+41.0%
8.3%US$3.00US$2.50n/a3
Dec ’23US$1.96
US$2.83
+44.6%
8.3%US$3.00US$2.50n/a3
Nov ’23US$2.62
US$3.67
+39.9%
17.0%US$4.50US$3.00n/a3
Oct ’23US$2.50
US$3.67
+46.7%
17.0%US$4.50US$3.00n/a3
Sep ’23US$2.55
US$3.67
+43.8%
17.0%US$4.50US$3.00n/a3
Aug ’23US$3.84
US$7.75
+101.8%
29.4%US$10.00US$5.00n/a4
Jul ’23US$4.02
US$10.13
+151.9%
5.4%US$11.00US$9.50n/a4
Jun ’23US$3.07
US$10.13
+229.8%
5.4%US$11.00US$9.50n/a4
May ’23US$4.09
US$18.00
+340.1%
29.9%US$25.00US$11.00n/a4
Apr ’23US$6.32
US$19.50
+208.5%
19.7%US$25.00US$15.00n/a4
Mar ’23US$8.07
US$26.50
+228.4%
14.2%US$30.00US$21.00n/a4
Feb ’23US$8.00
US$26.50
+231.3%
14.2%US$30.00US$21.00n/a4
Jan ’23US$11.56
US$28.25
+144.4%
15.1%US$32.00US$21.00US$2.014
Dec ’22US$10.99
US$28.25
+157.1%
15.1%US$32.00US$21.00US$1.964
Nov ’22US$14.65
US$28.25
+92.8%
15.1%US$32.00US$21.00US$2.624
Oct ’22US$11.76
US$30.25
+157.2%
10.6%US$35.00US$26.00US$2.504
Sep ’22US$17.38
US$31.50
+81.2%
12.0%US$35.00US$26.00US$2.554
Aug ’22US$18.05
US$31.50
+74.5%
12.0%US$35.00US$26.00US$3.844
Jul ’22US$26.23
US$31.50
+20.1%
12.0%US$35.00US$26.00US$4.024

Analyst Forecast: Target price is less than 20% higher than the current share price.


Discover undervalued companies